<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217733</url>
  </required_header>
  <id_info>
    <org_study_id>Sherief Protocol</org_study_id>
    <nct_id>NCT04217733</nct_id>
  </id_info>
  <brief_title>Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome</brief_title>
  <official_title>A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel
      syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel
      syndrome: Does this add to current treatment?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS</measure>
    <time_frame>6 months</time_frame>
    <description>the number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Mebeverine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mebeverine 3 times daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethosuximide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethosuxemide 3 times daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxyifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pentoxyifylline 2 times daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxyifylline</intervention_name>
    <description>Pentoxyifylline two times daily for 3 months</description>
    <arm_group_label>Pentoxyifylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mebeverine</intervention_name>
    <description>Mebeverine 3 times for 3 months</description>
    <arm_group_label>Mebeverine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethosuximide</intervention_name>
    <description>ethosuximide 3 times for 3 months</description>
    <arm_group_label>Ethosuximide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age ≥ 18 years,

               -  Man and Women, Negative pregnancy test and effective contraception,

               -  IBS defined by the Rome criteria IV

               -  During the previous seven days the inclusion visit, average numeric rating scale
                  (NRS) pain ≥ 4.

               -  IBS Treatment stable for 1 month

        Exclusion Criteria:

          -  • Breastfeeding

               -  Diabetic patients

               -  Significant liver function abnormalities (transaminases&gt; 3N, cholestasis) and
                  moderate renal disease (MDRD &lt;60 ml / min)

               -  Addiction to alcohol and / or drugs,

               -  Antiepileptic drugs taken (epilepsy or chronic pain)

               -  Chronic pain of greater intensity than that related to IBS,

               -  Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and
                  pentoxifylline.

               -  History or current severe depression (hospitalization, long-term antidepressant
                  treatment)

               -  Psychotic disorders,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Mahmoud Bahaa El dien, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacy department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahar El-Haggar, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical pharmacy Department- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahar Hegazy, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical pharmacy Department- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tropical Medicine Department- Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, ass. prof.</last_name>
    <phone>00201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam, Ass. Prof.</last_name>
      <phone>00201009221243</phone>
      <email>sheriefabdelsalam@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Ass. Prof. Tropical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethosuximide</mesh_term>
    <mesh_term>Mebeverine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

